Wiman K G
Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden.
Med Oncol. 1998 Dec;15(4):222-8. doi: 10.1007/BF02787204.
The p53 gene is frequently mutated in human tumours and therefore an important target for therapeutic intervention. Several p53-based strategies for treatment of cancer are currently under development. p53 gene therapy has resulted in tumour regression in patients with lung cancer. A mutant adenovirus can obliterate tumour cells carrying mutant p53 or lacking p53, but is unable to replicate in normal cells. Furthermore, current studies suggest that reactivation of mutant p53 proteins in tumours using small p53-activating molecules may initiate p53-dependent apoptosis and thus eliminate the tumour.
p53基因在人类肿瘤中经常发生突变，因此是治疗干预的重要靶点。目前正在开发几种基于p53的癌症治疗策略。p53基因疗法已使肺癌患者的肿瘤消退。一种突变腺病毒可以清除携带突变p53或缺乏p53的肿瘤细胞，但无法在正常细胞中复制。此外，目前的研究表明，使用小的p53激活分子在肿瘤中重新激活突变的p53蛋白可能引发p53依赖性凋亡，从而消除肿瘤。
